AstraZeneca diabetes drug reduces complications

AstraZeneca diabetes drug reduces complications

A drug developed by AstraZeneca has significantly reduced the likelihood of hospitalization of diabetic patients with heart failure, a type 2 diabetes-related condition.

The results of a large clinical trial represent a significant boost for the Anglo-Swedish pharmaceutical manufacturer, which aims to achieve ambitious sales targets.

Cardiovascular complications are common in people with type 2 diabetes, which has become a major burden on healthcare systems worldwide.

Leave a comment

Send a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.